Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-11-17

Clinical Trial Update: A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 study comparing CT-P17 to Humira in active rheumatoid arthritis has completed; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CT-P17 (adalimumab biosimilar)
  • Humira (adalimumab)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17